First-Line Therapy in Advanced Squamous Cell Carcinoma of the Anal Canal

Explore rising HPV-driven anal cancer burden and NCCN first-line choices, with trial data guiding chemo-immunotherapy patient selection.

PODIUM-03 shows retifanlimab plus carboplatin/paclitaxel boosts response and survival, reshaping first-line care for advanced anal cancer.

This segment focuses on the durability of benefit with first-line chemo-immunotherapy in advanced SCAC and how the POD1UM-303 findings are shaping real-world treatment decisions.

This segment addresses 2 key clinical questions following the adoption of chemo-immunotherapy in advanced SCAC: which patients benefit most and how long treatment should be continued.

This segment addresses one of the most pressing challenges in advanced SCAC: management after progression on first-line carboplatin, paclitaxel, and retifanlimab.